• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病(NAFLD)与慢性肾脏病(CKD)的发病率增加有关。

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD).

机构信息

Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.

Department of Surgery (A), University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany.

出版信息

Eur J Med Res. 2023 Apr 17;28(1):153. doi: 10.1186/s40001-023-01114-6.

DOI:10.1186/s40001-023-01114-6
PMID:37062837
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10108448/
Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the western world. The excess mortality in NAFLD patients is strongly related to extrahepatic comorbidities. Recently, an association between NAFLD and chronic kidney disease (CKD) has been reported in various populations.

METHODS

Based on the IQVIA Disease Analyzer database, this retrospective study examined two cohorts from Germany matched for sex, age, index year, annual visit frequency, hypertension, and diabetes, including 92,225 patients with and without NAFLD. The incidence of CKD was assessed as a function of NAFLD using Cox regression models.

RESULTS

A total of 92,225 NAFLD patients as well as 92,225 patients without NAFLD were included into analyses. CKD was diagnosed in 19.1% vs. 11.1% of patients with and without NAFLD within the 10 years observation period (p < 0.001). Cox regression confirmed a significant association between NAFLD and CKD with a hazard ratio (HR) of 1.80 (95%CI: 1.73-1.86, p < 0.001). Subgroup analyses revealed that this association was most pronounced in the age group of 18 to 50 years (HR: 2.13, 95%CI: 1.91-2.37, p < 0.001) and among female NAFLD patients (HR 1.85, 95%CI: 1.76-1.95, p < 0.001).

CONCLUSIONS

The results of this study confirm a significantly increased risk of developing CKD in a large, real-world cohort of adult NAFLD patients in Germany. Interdisciplinary care of NAFLD patients, which is currently gaining importance worldwide, should be considered to include systematic measures for prevention and/or early detection of CKD with the aim of minimizing long-term renal complications.

摘要

背景

非酒精性脂肪性肝病(NAFLD)是西方世界慢性肝病的主要原因。NAFLD 患者的超额死亡率与肝外合并症密切相关。最近,在各种人群中已经报道了 NAFLD 与慢性肾脏病(CKD)之间的关联。

方法

基于 IQVIA 疾病分析器数据库,这项回顾性研究检查了来自德国的两个队列,这些队列在性别、年龄、索引年、年度就诊频率、高血压和糖尿病方面相匹配,包括 92225 例有和无 NAFLD 的患者。使用 Cox 回归模型评估了 CKD 的发生率与 NAFLD 的关系。

结果

共有 92225 例 NAFLD 患者和 92225 例无 NAFLD 的患者被纳入分析。在 10 年的观察期内,有 CKD 的患者分别占患者的 19.1%和 11.1%(p<0.001)。Cox 回归证实了 NAFLD 与 CKD 之间的显著关联,风险比(HR)为 1.80(95%CI:1.73-1.86,p<0.001)。亚组分析显示,这种关联在 18 至 50 岁年龄组中最为明显(HR:2.13,95%CI:1.91-2.37,p<0.001),且在女性 NAFLD 患者中更为明显(HR 1.85,95%CI:1.76-1.95,p<0.001)。

结论

这项研究的结果证实,在德国一个大型的、真实世界的成年 NAFLD 患者队列中,CKD 的发生风险显著增加。目前,全球范围内正在重视对 NAFLD 患者的跨学科治疗,应该考虑将系统的预防和/或早期发现 CKD 的措施纳入其中,以最大限度地减少长期肾脏并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c5a/10108448/c4ab063acd57/40001_2023_1114_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c5a/10108448/c4ab063acd57/40001_2023_1114_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c5a/10108448/c4ab063acd57/40001_2023_1114_Fig1_HTML.jpg

相似文献

1
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD).非酒精性脂肪性肝病(NAFLD)与慢性肾脏病(CKD)的发病率增加有关。
Eur J Med Res. 2023 Apr 17;28(1):153. doi: 10.1186/s40001-023-01114-6.
2
Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease.非酒精性脂肪性肝病增加了发生慢性肾脏病的风险。
United European Gastroenterol J. 2020 Oct;8(8):942-948. doi: 10.1177/2050640620944098. Epub 2020 Jul 23.
3
Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.非酒精性脂肪性肝病与慢性肾脏病的临床转归。
Nephrol Dial Transplant. 2019 Mar 1;34(3):449-457. doi: 10.1093/ndt/gfx381.
4
Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities.非酒精性脂肪性肝病合并慢性肾脏病患者死亡率增加可由代谢性合并症解释。
Clin Res Hepatol Gastroenterol. 2019 Oct;43(5):542-550. doi: 10.1016/j.clinre.2019.02.004. Epub 2019 Mar 1.
5
Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.非酒精性脂肪性肝病与慢性肾脏病的关联:一项系统评价和荟萃分析
PLoS Med. 2014 Jul 22;11(7):e1001680. doi: 10.1371/journal.pmed.1001680. eCollection 2014 Jul.
6
Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study.非酒精性脂肪性肝病增加了发生进展性慢性肾脏病的风险:一项倾向评分匹配队列研究。
J Intern Med. 2019 Dec;286(6):711-722. doi: 10.1111/joim.12964. Epub 2019 Aug 23.
7
Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients.非酒精性脂肪性肝病 (NAFLD) 与新发心力衰竭风险:对 173966 例患者的回顾性分析。
Clin Res Cardiol. 2023 Oct;112(10):1446-1453. doi: 10.1007/s00392-023-02250-z. Epub 2023 Jul 6.
8
Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.非酒精性脂肪性肝病的纤维化风险与老年 2 型糖尿病患者的慢性肾脏病有关。
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3661-e3669. doi: 10.1210/clinem/dgac382.
9
The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.非酒精性脂肪肝疾病和肝纤维化对慢性肾脏病患者不良临床结局和死亡率的影响:利用英国生物库的前瞻性队列研究。
BMC Med. 2023 May 18;21(1):185. doi: 10.1186/s12916-023-02891-x.
10
The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.日本非酒精性脂肪性肝病患者慢性肾脏病的发展
Intern Med. 2011;50(10):1081-7. doi: 10.2169/internalmedicine.50.5043. Epub 2011 May 1.

引用本文的文献

1
The Underdiagnosis of Chronic Kidney Disease in Patients with a Documented Estimated Glomerular Filtration Rate and/or Urine Albumin-Creatinine Ratio in Germany.德国估算肾小球滤过率和/或尿白蛋白肌酐比值记录在案的患者中慢性肾脏病的诊断不足情况
Medicina (Kaunas). 2025 May 2;61(5):843. doi: 10.3390/medicina61050843.
2
Construction and validation of a nomogram for detecting chronic kidney disease in patients with nonalcoholic fatty liver disease: Insights from the NHANES database.非酒精性脂肪性肝病患者慢性肾脏病检测列线图的构建与验证:来自美国国家健康与营养检查调查(NHANES)数据库的见解
Clinics (Sao Paulo). 2025 May 7;80:100686. doi: 10.1016/j.clinsp.2025.100686. eCollection 2025.
3

本文引用的文献

1
Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中心血管疾病的病理生理机制
Gastroenterol Hepatol Bed Bench. 2022 Summer;15(3):194-203. doi: 10.22037/ghfbb.v15i3.2549.
2
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.非酒精性脂肪性肝病:一种需要多学科和整体方法的多系统疾病。
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):578-588. doi: 10.1016/S2468-1253(21)00020-0. Epub 2021 May 4.
3
Non-alcoholic fatty liver disease.
Characterization of gut dysbiosis and intestinal barrier dysfunction in patients with metabolic dysfunction-associated steatotic liver disease and chronic kidney disease: a comparative study.
代谢功能障碍相关脂肪性肝病和慢性肾脏病患者肠道菌群失调及肠屏障功能障碍的特征:一项比较研究
Sci Rep. 2025 May 3;15(1):15481. doi: 10.1038/s41598-025-00237-6.
4
From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease.从肝脏到肾脏:慢性肾脏病中非酒精性脂肪性肝病被忽视的负担
J Clin Med. 2025 Apr 5;14(7):2486. doi: 10.3390/jcm14072486.
5
Transcription factor specificity protein (SP) family in renal physiology and diseases.转录因子特异性蛋白(SP)家族在肾脏生理学及疾病中的作用
PeerJ. 2025 Jan 20;13:e18820. doi: 10.7717/peerj.18820. eCollection 2025.
6
Artificial intelligence in predicting chronic kidney disease prognosis. A systematic review and meta-analysis.人工智能在预测慢性肾脏病预后中的应用。一项系统评价与Meta分析。
Ren Fail. 2024 Dec;46(2):2435483. doi: 10.1080/0886022X.2024.2435483. Epub 2024 Dec 11.
7
Association between liver fibrosis scores and short-term clinical outcomes in hospitalized chronic kidney disease patients: a prospective observational study.住院慢性肾脏病患者肝纤维化评分与短期临床结局的关联:一项前瞻性观察研究。
Front Med (Lausanne). 2024 Aug 20;11:1387472. doi: 10.3389/fmed.2024.1387472. eCollection 2024.
8
Epicardial and liver fat implications in albuminuria: a retrospective study.心外膜和肝脂肪对白蛋白尿的影响:一项回顾性研究。
Cardiovasc Diabetol. 2024 Aug 22;23(1):308. doi: 10.1186/s12933-024-02399-5.
9
Epidemiology of metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的流行病学
Clin Mol Hepatol. 2025 Feb;31(Suppl):S32-S50. doi: 10.3350/cmh.2024.0431. Epub 2024 Aug 19.
10
Nomogram for predicting 5-year metabolic dysfunction-associated steatotic liver disease risk: retrospective cohort study.预测5年代谢功能障碍相关脂肪性肝病风险的列线图:回顾性队列研究
Endocr Connect. 2024 Jul 13;13(8). doi: 10.1530/EC-24-0186. Print 2024 Aug 1.
非酒精性脂肪性肝病。
Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21.
4
Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者的肿瘤发病率。
Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724. doi: 10.3238/arztebl.2020.0719.
5
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.非酒精性脂肪性肝病与新发慢性肾脏病风险:一项更新的荟萃分析。
Gut. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082. Epub 2020 Dec 10.
6
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum.非酒精性脂肪性肝病-非酒精性脂肪性肝炎临床试验中饮食和运动的标准化:肝脏论坛的建议。
J Hepatol. 2020 Sep;73(3):680-693. doi: 10.1016/j.jhep.2020.04.030. Epub 2020 Apr 27.
7
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义:国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
8
Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?代谢性炎症——肝脏炎症通路在非酒精性脂肪性肝病合并症发生中作为驱动因素的作用?
Gastroenterology. 2020 May;158(7):1929-1947.e6. doi: 10.1053/j.gastro.2020.02.020. Epub 2020 Feb 15.
9
NAFLD as a driver of chronic kidney disease.非酒精性脂肪性肝病作为慢性肾脏病的一个驱动因素。
J Hepatol. 2020 Apr;72(4):785-801. doi: 10.1016/j.jhep.2020.01.013. Epub 2020 Feb 12.
10
Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany.非酒精性脂肪性肝病对德国初级保健人群心血管疾病发病率的影响。
Dig Dis Sci. 2020 Jul;65(7):2112-2119. doi: 10.1007/s10620-019-05986-9. Epub 2019 Dec 3.